Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Dec;29(12):967-968.
doi: 10.1038/s41422-019-0253-5.

BAX and BAK become killers without a BH3 trigger

Jerry M Adams  1
Affiliations
Comment

BAX and BAK become killers without a BH3 trigger

Jerry M Adams. Cell Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Figures

Fig. 1
Fig. 1
Models for the activation of BAK and BAX to drive apoptosis. a The direct activation model posits that BH3-only proteins are either sensitizers (e.g., BAD), which can only engage and neutralize pro-survival family members, or activators (e.g., BIM and activated BID (tBID)), which can also bind BAX and BAK and trigger their rearrangement into lethal oligomeric forms that damage the MOM and seal commitment to apoptosis. b The indirect activation model suggests that BH3-only proteins can only engage pro-survival family members, but certain ones are more potent because they can bind and neutralize all pro-survival members (are promiscuous), whereas others (like BAD and NOXA) are less potent because they are selective for a subset of pro-survival members. c The membrane-mediated permissive Model is an indirect activation model that emphasizes BCL-XL and MCL-1 as key targets for inactivation by BH3-only proteins to free BAX and BAK for death duty. In this model, once freed from pro-survival restraint, activation of BAX and BAK is autonomous, probably requiring only association with the MOM for BAX
See this image and copyright information in PMC

Comment on

References

    1. Adams JM, Cory S. Cell Death Differ. 2018;25:27–36. doi: 10.1038/cdd.2017.161. - DOI - PMC - PubMed
    1. Letai A, et al. Cancer Cell. 2002;2:183–192. doi: 10.1016/S1535-6108(02)00127-7. - DOI - PubMed
    1. Chen L, et al. Mol. Cell. 2005;17:393–403. doi: 10.1016/j.molcel.2004.12.030. - DOI - PubMed
    1. Willis SN, et al. Science. 2007;315:856–859. doi: 10.1126/science.1133289. - DOI - PubMed
    1. Llambi F, et al. Mol. Cell. 2011;44:517–531. doi: 10.1016/j.molcel.2011.10.001. - DOI - PMC - PubMed

MeSH terms

Substances